The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | CD20 targeted CAR-T: MB-106 in B-NHL and CLL
Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, gives an overview of the use of MB-106, a 3rd generation CD20-targeted chimeric antigen receptor (CAR) T-cell therapy, for the treatment of B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL). A Phase I/II trial (NCT03277729) investigating the safety and efficacy of MB-106 for high-risk B-NHL and CLL has reported a complete response rate of 82% amongst 11 patients with follicular lymphoma. No grade three or four cytokine release syndrome has been reported in patients with follicular lymphoma. A patient with high-risk CLL had a complete response to MB-106 with no detectable measurable residual disease (MRD). Dr Shadman comments on these findings, highlighting MB-106’s promising safety profile. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
